Introduction
Prostate cancer (PC) is the most common cancer among men in the United States, with an annual incidence of 192 280. 1 The introduction of PSA screening for PC has resulted in a dramatic increase in the diagnosis and stage migration, with a significant number of newly diagnosed patients having clinically localized low-risk PC. 2 In a recent review, Klotz 3 reported 90% of low-risk PC patients undergo treatment. He also concluded that to prevent one low-risk PC death, 80-100 men need to be treated. 3 Although 17-20% of men are destined to have PC during their lifetime, only 3% die from PC. 4, 5 Autopsy studies report a high rate of PC in men dying from other causes. 6, 7 The reported incidence varies from 11 to 33% depending on age, reaching 80% in men over the age of 90 years. 8 Total prostatectomy (TP) is the most common treatment approach for clinically localized PC. 9 TP is associated with significant treatment-related morbidity and quality of life impairment such as impotence and incontinence. Clearly, there is a subset of newly diagnosed PC patients who are not benefiting from aggressive intervention.
Active surveillance (AS) with delayed intervention has emerged as an effective alternative management strategy to immediate treatment. By following a rigid surveillance protocol, AS aims to avoid overtreatment of patients at a low risk of dying from PC. Regular PSA testing, digital rectal examination (DRE) and interval prostate biopsies are performed. Thereby only clinically significant PC is treated, sparing those patients who continue to be at low risk for progression.
As TP and AS are associated with different services offered by the urologist, the cumulative reimbursement for both management plans are different. We compare the urologist's reimbursement for managing low risk localized PC by either AS or TP (open and robotic assisted).
Materials and methods
We calculated the cumulative reimbursement for the urologist for managing low-risk PC by AS or TP over a period of 10 years. Medicare reimbursement values were used to maintain uniformity.
Our AS protocol (protocol A) involves outpatient visits every 3 months during the first 2 years and every 6 months thereafter. A PSA and DRE are performed at each visit. Transrectal ultrasound (TRUS)-guided biopsies are performed within the first year after diagnosis and every year afterward. PSA velocity of 0.75 ng per year and abnormal DRE were indications for a biopsy. Another AS protocol involves less frequent TRUS-guided biopsies to be every 1-3 years, with approximately five TRUS-guided biopsies over the 10-year period. The interval between biopsies is shorter during the early years after diagnosis (protocol B). 10 When TP is performed, the patient will follow-up with the urologist at 1 week, 6 weeks, every 3 months during the first year, every 6 months during the following 4 years and yearly thereafter.
Reimbursement values were obtained from (http:// medicare.fcso.com/Fee_lookup/). We used the reimbursement values for one region in Florida (Miami). For reimbursement from follow-up visits, we used level three follow-up visits. Costs other than the urologist reimbursement (operating room, anesthesia, medications, hospital stayy) were out of the scope of the study.
The urologist is reimbursed $1905 as a surgical fee for performing open TP, $2939 for robotic-assisted TP, $595 for a TRUS-guided biopsy and $72 for each follow-up visit. Following TP, patient visits during the first 90 days (global period) are covered at no cost. We corrected for a 15% chance of having TP after being on AS at 5 years. 10 This was distributed as a 7.5% chance at third year and another 7.5% at fifth year follow-up.
Results
For performing open TP and following the patient, the cumulative reimbursement for the urologist is $2121, $2265, $2697 and $3057 at 1, 2, 5 and 10 years follow-up, respectively. For robotic-assisted TP, the cumulative urologist reimbursement is $3155, $3299, $3731 and $4091 at 1, 2, 5 and 10 years follow-up, respectively. Although for AS with protocol A, the urologist is expected to be reimbursed $883, $1766, $4269, $7964 at 1, 2, 5 and 10 years follow-up, respectively, assuming a 15% chance of having TP after being on AS by 5 years (Table 1) . For protocol B, the urologist earns $883, $1766, $2793, $4703 at 1, 2, 5 and 10 years follow-up, respectively, with 3 monthly visits during the first 2 years (Figure 1 ). TP and AS have different trends in terms of urologist reimbursement. For TP, the urologist receives $1905 surgeon fee and $72 for each follow-up visit after the 90 days global period. For AS, the urologist reimbursement is $72 for each follow-up visit and $595 for each TRUS-guided biopsy.
After 1 year of following a patient on AS, the urologist is expected to be reimbursed $883 (41% of his reimbursement from open TP at 1 year). At 2 years follow-up, the urologist will be reimbursed $1766 (78% of open TP reimbursement at 2 years). At 3 years follow-up, the urologist reimbursements from AS and open TP are nearly equal. At 4 years, the urologist reimbursements from AS and robotic-assisted TP are almost equal ( Figure 2) ; thereafter, AS starts to yield higher reimbursement (accounting for the 15% chance for the patient to have TP after being on AS). 
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Discussion
The United States has the most expensive health-care system in the world. 11 During the last few years, healthcare cost has been rising and exceeding the inflation rate, 11 whereas simultaneously the medical reimbursement is declining. 12 Lotan et al. 13 reported a significant decline in reimbursement rates per hour of labor for surgical procedures, with nearly a 30% decline from 1995 to 2004. Reimbursement is an essential component of any medical or surgical practice. Physicians, in general, lack knowledge of reimbursement. 14 Madan et al. 15 reported the lack of clear understanding among residents and attending surgeons about the reimbursement patterns including that for common procedures such as laparoscopic cholecystectomy. In this study, we compared the reimbursement pattern for AS opposed to TP for clinically localized low-risk PC.
AS is a reasonable management strategy for men with localized low-risk PC. The American Urological Association guidelines on management of clinically localized PC consider AS a viable monotherapy for clinically localized low-risk PC, along with other options including TP and radiation therapy. 16 Although the ideal protocol for monitoring a patient on AS is still being defined, the National Comprehensive Cancer Network guidelines recommend a stringent protocol with a PSA as often as 3 months and at least 6 months, DRE every 6 months and at least 12 months, and needle biopsy as often as annually for patients with a life expectancy of 410 years and less often for patients with o10 years. 17 Hence, it is apparent that AS relies heavily on a long and consistent patientphysician interaction.
Urologists may believe AS being a conservative approach will lead to lower reimbursement. The management plans have different patterns in terms of reimbursement. The urologist will be reimbursed higher immediately following TP and then $72 for each follow-up visit beyond the global period (the first 90 days following TP). In case of AS, the reimbursement increases with each TRUS-guided biopsy performed and follow-up visit. Reimbursements from both the management strategies are approximately the same at 3 years follow-up.
Our study has limitations. We did not account for inflation and other factors affecting reimbursement; however, we find that these factors are more likely to affect both groups equally. There are regional variations in Medicare reimbursement, these variations are minor and would not significantly affect the results of the study. Although it is desirable to include the reimbursement of managing complications, we find complications management is extremely variable and difficult to standardize. Furthermore, management of complications (impotence and incontinence) by surgical intervention is most likely performed by another specialized urologist; therefore, it will not affect the reimbursement of the urologist who initially performed TP.
Conclusion
The reimbursement for the urologist from AS and TP have different trends. TP has a higher reimbursement initially due to the surgical fee. AS yields higher reimbursement after 4 years because of the need for TRUS-guided biopsies. Offering different management alternative should be for the patients' best interest regardless of the reimbursement.
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